Table 5.
List of drugs failed the NRDL admission by using OS as the primary endpoint.
| Generic name | Company | Indication | Date of marketing |
|---|---|---|---|
| Gilteritinib fumarate tablets | Astellas Pharma Inc. | Acute myeloid leukemia | Jan. 30th, 2021 |
| Radium [223Ra] chloride injection | Bayer AG | Castration- resistant prostate cancer | Aug. 26th, 2020 |
| Trifluridine and tipiracil hydrochloride tablets | Taiho Pharmaceutical Co., Ltd. | Metastatic colorectal cancer | Aug. 29th, 2019 |
| Venetoclax tablets | Abbvie Ireland Nl BV | Acute myelogenous leukemi | Dec. 2nd, 2020 |
| Nivolumab injection | Ristol-Myers Squibb Holdings Pharma | Non-small-cell lung cancer | Jun. 15th, 2018 |
| Nivolumab injection | Ristol-Myers Squibb Holdings Pharma | Squamous cell carcinoma of the head and neck | Sept. 29th, 2019 |
| Nivolumab injection | Ristol-Myers Squibb Holdings Pharma | gastric cancer and adenocarcinoma of Esophagogastric junction | Mar. 12th, 2020 |
| Nivolumab injection | Ristol-Myers Squibb Holdings Pharma | malignant pleural mesothelioma | Jun. 8th, 2021 |
| Pembrolizumab injection | Merck Sharp and Dohme Corp., a subsidiary of Merck and Co., Inc. | Non-small-cell lung cancer | Sept. 29th, 2019 |
| Pembrolizumab injection | Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. | Esophageal squamous cell carcinoma | Jun. 17th, 2020 |
| Ipilimumab injection | Bristol-Myers Squibb Pharma EEIG | Malignant pleural mesothelioma | Jun. 8th, 2021 |